Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q&A: AbbVie VP Lin On Filling Humira's Big Shoes In Immunology

Executive Summary

AbbVie's Shao-Lee Lin talks about drug candidates that the company hopes will extend its legacy in immunology, which is built on the foundation of the world's top-selling biopharma product Humira.


Related Content

HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
AbbVie's New Generation JAK inhibitor Looks Good But CV Specter Looms
Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts